| Period | Period Low | Period High | Performance | |
|---|---|---|---|---|
|
1-Month
|
1,774.000
+21.42%
on 01/20/26
|
|
2,219.000
-2.93%
on 02/09/26
|
+268.000
(+14.21%)
since 01/09/26
|
|
3-Month
|
1,753.000
+22.88%
on 11/21/25
|
|
2,219.000
-2.93%
on 02/09/26
|
+382.000
(+21.56%)
since 11/10/25
|
|
52-Week
|
1,242.500
+73.36%
on 04/09/25
|
|
2,219.000
-2.93%
on 02/09/26
|
+688.500
(+46.98%)
since 02/10/25
|
Sixteen organizations, awarded funding in 2025, are taking innovative, local approaches to boosting vaccination in communities across the US Grant recipients’ projects aim to modernize...
Grant funding awarded to support lupus-focused community programs across the United States
A plan to slash Food and Drug Administration drug review times is raising alarms at the public health agency that's been rocked by recent layoffs and resignations
Exdensur is the first and only ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype Approval based...
Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...
New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track...
December S&P 500 E-Mini futures (ESZ25) are up +0.48%, and December Nasdaq 100 E-Mini futures (NQZ25) are up +0.63% this morning, pointing to a higher open on Wall Street as Treasury yields moved lower,...
GSK and the National Senior Games team up to spotlight RSV risk, prevention, and the power of proactive health conversations National TV special “Redefining...
Prefilled syringe presentation offers a convenient administration option to healthcare professionals An estimated one million people develop shingles...
The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.
Long term indicators fully support a continuation of the trend.
Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.
| 3rd Resistance Point | 2,263.000 |
| 2nd Resistance Point | 2,241.000 |
| 1st Resistance Point | 2,200.000 |
| Last Price | 2,133.000 |
| 1st Support Level | 2,137.000 |
| 2nd Support Level | 2,115.000 |
| 3rd Support Level | 2,074.000 |
| 52-Week High | 2,219.000 |
| Last Price | 2,133.000 |
| Fibonacci 61.8% | 1,845.977 |
| Fibonacci 50% | 1,730.750 |
| Fibonacci 38.2% | 1,615.523 |
| 52-Week Low | 1,242.500 |